相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Re-epithelialization and immune cell behaviour in an ex vivo human skin model
Ana Rakita et al.
SCIENTIFIC REPORTS (2020)
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors
Paul Savage et al.
COMMUNICATIONS BIOLOGY (2020)
Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
Margarite D. Matossian et al.
BMC CANCER (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene
Suvimol Niyomnaitham et al.
PEERJ (2019)
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Gloria V. Echeverria et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Genomic evolution of cancer models: perils and opportunities
Uri Ben-David et al.
NATURE REVIEWS CANCER (2019)
Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer
Tia H. Turner et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer
Gloria V. Echeverria et al.
NATURE COMMUNICATIONS (2018)
KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells
Meng Jiang et al.
ONCOTARGET (2017)
A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).
Clinton Yam et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Planning bioinformatics workflows using an expert system
Xiaoling Chen et al.
BIOINFORMATICS (2017)
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Lacey E. Dobrolecki et al.
CANCER AND METASTASIS REVIEWS (2016)
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Alejandra Bruna et al.
CELL (2016)
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner et al.
NATURE METHODS (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
I. Lohse et al.
BRITISH JOURNAL OF CANCER (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Brinton Seashore-Ludlow et al.
CANCER DISCOVERY (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Peter Eirew et al.
NATURE (2015)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Benoit Tessoulin et al.
BLOOD (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Computational analysis of image-based drug profiling predicts synergistic drug combinations: Applications in triple-negative breast cancer
Miriam B. Brandl et al.
MOLECULAR ONCOLOGY (2014)
PyClone: statistical inference of clonal population structure in cancer
Andrew Roth et al.
NATURE METHODS (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer
Zachary C. Dobbin et al.
ONCOTARGET (2014)
Xenome-a tool for classifying reads from xenograft samples
Thomas Conway et al.
BIOINFORMATICS (2012)
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
Cynthia X. Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
Kyle D. Holen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PRIMA-1(MET) inhibits growth of mouse tumors carrying mutant p53
Nicole Zache et al.
CELLULAR ONCOLOGY (2008)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
NATURE REVIEWS CANCER (2006)
分享论文
